EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary peptidomic classifier for the non-invasive diagnosis of Alport syndrome

Julia Byrska iD, Elena Goma Garces, Justyna Siwy, Harald Mischak, Margarita Kondyli, Lorenzo Catanese, Monica Furlano, Melissa Pilco-Teran, Beatriz Fernandez-Fernandez, Ana Belen Sanz, Roser Torra, Maria Dolores Sanchez-Niño und 3 weitere

Nephrology Dialysis Transplantation · 14.11.2026

DOI: 10.1093/ndt/gfag212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 14.11.2026. Verfasst von Julia Byrska und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Mad…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis Alport syndrome (AS) is an inherited glomerular disease that often presents with non-specific clinical and histological features overlapping with other forms of chronic kidney disease (CKD). Consequently, AS may remain unrecognised or misclassified, particularly where genetic testing is unavailable and biopsy is delayed or infeasible. We hypothesised that a non-invasive urinary peptide signature can distinguish AS from other CKD aetiologies, patients with diabetes and healthy individuals.

Methods

In this multicentre study, we included 165 adults with genetically confirmed AS. Comparator groups comprised patients with non-Alport CKD, diabetes and healthy individuals, matched to the AS cohort by age, sex and estimated glomerular filtration rate (eGFR). Urinary peptide profiles were generated by capillary electrophoresis–mass spectrometry. Group differences in peptide abundance were analysed, and a supervised multipeptide classifier specific for AS was constructed and evaluated in matched test cohorts and in two external validation cohorts: 145 patients with IgA nephropathy (IgAN) and 15 further patients with AS.

Results

We identified 419 urinary peptides that differed between AS and comparator groups, of which 178 were incorporated into the AS-specific classifier Alport178. In matched test cohorts, Alport178 achieved an AUC of 0.999 (95% CI 0.997–1.00), with 100% sensitivity for AS and high specificity in CKD, diabetic and healthy control groups. In external validation cohorts, the classifier identified most AS cases and classified the majority of IgAN patients as non-Alport. The most informative peptides were predominantly collagen alpha chain fragments.

Conclusion

A urinary peptidomic classifier specific for AS enables differentiation of AS from other CKD entities, patients with diabetes, healthy individuals and IgAN. This non-invasive approach may facilitate earlier recognition of AS, reduce the need for invasive diagnostic procedures and prioritise patients for confirmatory genetic testing and targeted management.

Schlagwörter

Stichwörter der Autor:innen

Alport syndromebiomarkerschronic kidney diseasepeptidomicsurinary proteomics

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, Madrid, Spain.
  • Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Mosaiques Diagnostics, Hannover, Germany.
  • Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.
  • Department of Nephrology, Medizincampus Oberfranken, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Julia Byrska

Zitieren

APA

Byrska, J., Goma Garces, E., Siwy, J., Mischak, H., Kondyli, M., Catanese, L., Furlano, M., Pilco-Teran, M., Fernandez-Fernandez, B., Belen Sanz, A., Torra, R., Sanchez-Niño, M. D., Ortiz, A., Perez Gomez, M. V., & Alport Marató TV3 working group (2026). Urinary peptidomic classifier for the non-invasive diagnosis of Alport syndrome. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag212

Vancouver

Byrska J, Goma Garces E, Siwy J, Mischak H, Kondyli M, Catanese L, et al. Urinary peptidomic classifier for the non-invasive diagnosis of Alport syndrome. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag212

BibTeX
@article{Byrska2026,
  author = {Byrska, Julia and Goma Garces, Elena and Siwy, Justyna and Mischak, Harald and Kondyli, Margarita and Catanese, Lorenzo and Furlano, Monica and Pilco-Teran, Melissa and Fernandez-Fernandez, Beatriz and Belen Sanz, Ana and Torra, Roser and Sanchez-Niño, Maria Dolores and Ortiz, Alberto and Perez Gomez, Maria Vanessa and Alport Marató TV3 working group, Alport Marató TV3 working group},
  title = {Urinary peptidomic classifier for the non-invasive diagnosis of Alport syndrome},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag212}
}
Kostenlos starten →